...NYSE:BHVN) 6/18/19 $300.0 $2,209.0 $2,244.7 2% Ampio Pharmaceuticals Inc. (NASDAQ:AMPE) 6/17/19 $12.0 $56.6 $55.1 -3% Sellas...

...University and was previously CMO, EVP and head of R&D of Galena Biopharma Inc., now Sellas Life Sciences Group Ltd....

...as SVP, general counsel. He was general counsel of Galena Biopharma Inc., which merged with Sellas...

...in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort. Sellas...
...in TNBC and plans to advance NeuVax's development through a partnership or other strategic collaboration. Sellas...
...The single-blind, U.S., investigator-sponsored trial enrolled 275 patients overall with node-positive breast cancer or TNBC. Sellas...

...in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort. Sellas...
...in TNBC and plans to advance NeuVax's development through a partnership or other strategic collaboration. Sellas...
...IHC). The single-blind, investigator-sponsored trial enrolled 275 patients overall with node-positive breast cancer or TNBC. Sellas...

...In September, Sellas Life Sciences Group Ltd. (Hamilton, Bermuda) reported data from 20 patients with multiple myeloma (MM) in a...
...is a vaccine comprising WT1 peptides administered in combination with an adjuvant and immune modulator. Sellas Life Sciences Group Ltd....
...survival (DFS), overall survival (OS), safety and WT1 expression Status: Phase II data Milestone: NA Claire Quang galinpepimut-S Sellas Life Sciences Group Ltd. Wilms...

...Sellas Life Sciences Group Ltd., Hamilton, Bermuda Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Jennie Walters galinpepimut-S Keytruda Merck & Co. Inc. Sellas...

...named Jonathan Eckard chief scientific affairs officer. He was chief business and strategy officer of Sellas...

...Sellas Life Sciences Group Inc. The combined company's pipeline will include galinpepimut-S ( WT1 vaccine). Sellas...
...of Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas...
...options to monetize its clinical programs, including a sale, merger, reverse merger or combining companies. Sellas...

...form Sellas Life Sciences Group Inc. The combined company's pipeline will include galinpepimut-S (WT1 vaccine). Sellas...
...of Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas...
...options to monetize its clinical programs, including a sale, merger, reverse merger or combining companies. Sellas...